Fluorolintane
Fluorolintane (2-F-DPD) is a fluorinated diarylethylamine dissociative related to diphenidine, appearing as a research chemical in the late 2010s. It is presumed to act as an NMDA receptor antagonist producing dose-dependent dissociation and anaesthesia. There is essentially no formal human data, and its profile is inferred from diphenidine and anecdote.
01 Overview
Fluorolintane is a minor, poorly studied member of the diphenidine family carrying a fluorine substituent. It has not been examined clinically, and knowledge rests almost entirely on user reports and structural analogy.
Reported effects follow the class pattern: light dissociation and stimulation at lower doses, heavy dissociation, ataxia and confusion at higher doses. Onset is slow and duration moderate to long, so redosing is a notable overdose risk.
02 Mechanism
Presumed non-competitive NMDA receptor antagonist; a fluorinated diarylethylamine analogue of diphenidine.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light (uncertain) | 30–50 mg | Oral | Estimated from diphenidine; poorly characterised. |
| Common (uncertain) | 50–100 mg | Oral | Slow onset; high redosing risk. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| DissociationDetachment and depersonalisation similar to diphenidine. | Anecdotal | ||
| StimulationMild energising effect reported at lower doses. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Ataxia and loss of coordinationUnsteady gait and impaired coordination with fall risk. | Moderate | Dose-dependent | Anecdotal | |
| Confusion and disorientationDisorientation and confusion likely at higher doses, especially with redosing. | Moderate | At higher doses | Unconfirmed |